TriangleNCT02409342 · OUTCOME
Percentage of Participants With at Least One Adverse Event
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)
What was measured
Percentage of participants with at least one adverse event.
Analysis population: Safety analyses included treated participants, defined as randomized participants who received any amount of study treatment.
Groups in this outcome
Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
Atezolizumab
Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
| Group | Source count |
|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 263 |
| Atezolizumab | 286 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 95.1 | Not reported | Not reported | Not reported | Not reported |
| Atezolizumab | 92.3 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 95.1
- group Id
- OG001
- value
- 92.3
- denoms
- counts
- group Id
- OG000
- value
- 263
- group Id
- OG001
- value
- 286
- units
- Participants
- description
- Percentage of participants with at least one adverse event.
- groups
- description
- Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
- id
- OG000
- title
- Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
- description
- Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
- id
- OG001
- title
- Atezolizumab
- param Type
- NUMBER
- population Description
- Safety analyses included treated participants, defined as randomized participants who received any amount of study treatment.
- reporting Status
- POSTED
- time Frame
- Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)
- title
- Percentage of Participants With at Least One Adverse Event
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice